Spots Global Cancer Trial Database for Rapamycin in Combination With Low-dose Aracytin in Elderly Acute Myeloid Leukemia Patients
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Rapamycin in Combination With Low-dose Aracytin in Elderly Acute Myeloid Leukemia Patients
Official Title: Rapamycin in Combination With Low-dose Aracytin in Elderly Acute Myeloid Leukemia Patients. A Study From the Groupe Ouest Est d'étude Des Leucémies Aiguës Myéloïdes (GOELAMS)
Study ID: NCT00235560
Conditions
Interventions
Study Description
Brief Summary: These study is designed to evaluate the tolerability and efficacy of sirolimus (rapamycin) in combination with low-dose aracytin in elderly AML.
Detailed Description: Evaluate the tolerability and efficacy of sirolimus (rapamycin) in combination with low-dose aracytin
Eligibility
Minimum Age: 60 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Service d'Hématologie, CHU, Angers, , France
Service d'Hématologie, Hôpital Jean Minjoz, BESANçON, , France
Service d'Hématologie CHU Purpan, Toulouse, , France
Contact Details
Name: RECHER Christian
Affiliation: CHU Toulouse
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
